SYRE Q3 2025 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$45M

Operating Income

-$57M

Net Income

-$11M

EPS (Diluted)

$-0.15

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$505M

Total Liabilities

$50M

Stockholders' Equity

$455M

Cash & Equivalents

$65M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$45M	$0	—
Operating Income	-$57M	-$55M	-2.7%
Net Income	-$11M	-$69M	+83.8%